Monday, 5 October 2026European Markets

NORBIT Stock Bullish Momentum With A 29% Rise In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORBIT (Oslo Børs Benchmark Index_GI: NORBT.OL) jumped by a staggering 29.38% in 21 sessions from kr40.5 to kr52.40 at 14:37 EST on Friday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is jumping 1.03% to kr1,223.44, after three consecutive sessions in a row of losses.

NORBIT's last close was kr49.20, 6.72% above its 52-week high of kr46.10.

About NORBIT

Norbit ASA provides technology products and solutions. It operates through Oceans, Connectivity, and Product Innovation and Realization segments. The company offers multibeam sonar systems, including integrated bathymetric systems, bathymetry systems, advanced monitoring systems for dredging, construction and renewables, forward looking wide area imaging, advanced imaging systems for obstacle avoidance/MCM, and above water laser products under the NORBIT WINGHEAD, NORBIT WBMS, NORBIT NORdredge, and NORBIT FLS names; customized cable assemblies, electromechanical box builds, and operational solutions; SeaCOP, a sensor integration platform and user interface common operational picture for emergency response; SECurus provides thermal and daylight stabilized camera solutions; SeaView, which offers thermal and daylight, pan, tilt, and zoom for environmental monitoring, and security and general surveillance; and SeaDarQ, a radar processing solution. It also provides sensing solutions for detecting threats at sea plus waterside security above and below the surface; FCL600, an underwater light solution for aquaculture industry; iData, which offers vehicle monitoring, telematics services, and fleet management for asset and vehicle management; and dedicated short-range communication technology for traffic system and vehicle application. In addition, the company offers research and development services, and contract manufacturing to industrial customers; and sells products based on proprietary technology, including special instrumentation n based on radar, radio frequency, and embedded signal processing technology. The company was founded in 1995 and is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, NORBIT has a trailing twelve months EPS of kr1.92.

PE Ratio

NORBIT has a trailing twelve months price to earnings ratio of 27.29. Meaning, the purchaser of the share is investing kr27.29 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.45%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NORBIT's stock is considered to be oversold (<=20).

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on May 5, 2023, the estimated forward annual dividend rate is 0.7 and the estimated forward annual dividend yield is 1.53%.

Volume

Today's last reported volume for NORBIT is 74164 which is 91.3% above its average volume of 34051.

More news about NORBIT (NORBT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com
NORBIT Stock Bullish Momentum With A 29% Rise In The Last 21 Sessions | ViaNews EU